super avana
| Product dosage: 160mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 36 | $5.29 | $190.45 (0%) | 🛒 Add to cart |
| 60 | $5.07 | $317.42 $304.32 (4%) | 🛒 Add to cart |
| 88 | $4.96 | $465.54 $436.32 (6%) | 🛒 Add to cart |
| 120 | $4.90
Best per pill | $634.83 $587.47 (7%) | 🛒 Add to cart |
Super Avana is a combination pharmaceutical product primarily indicated for the treatment of erectile dysfunction (ED) and premature ejaculation (PE). It contains two active pharmaceutical ingredients: Avanafil, a potent phosphodiesterase type 5 (PDE5) inhibitor, and Dapoxetine, a selective serotonin reuptake inhibitor (SSRI). This dual-action approach targets two of the most common male sexual health concerns simultaneously, making it a unique therapeutic option in urological and andrological practice. The formulation is typically available in a fixed-dose combination tablet, designed for on-demand use approximately 30-60 minutes prior to anticipated sexual activity.
1. Introduction: What is Super Avana? Its Role in Modern Medicine
Super Avana represents a significant advancement in sexual medicine by addressing two highly prevalent and often comorbid conditions. Erectile dysfunction affects approximately 30 million men in the United States alone, with prevalence increasing with age. Premature ejaculation, while less frequently discussed, impacts an estimated 20-30% of adult males globally. The combination of these conditions can create a complex clinical picture where each condition potentially exacerbates the other, creating what we often call the “sexual dysfunction cascade” in clinical practice.
What makes Super Avana particularly noteworthy is its targeted approach to this dual pathology. Rather than treating each condition separately with multiple medications, this combination therapy offers a streamlined treatment option that addresses both physiological (ED) and neuropsychological (PE) components of sexual dysfunction. The development of this combination reflects the growing understanding that sexual health conditions rarely exist in isolation and that comprehensive treatment often requires multi-modal approaches.
2. Key Components and Bioavailability of Super Avana
The therapeutic efficacy of Super Avana hinges on the specific pharmacological properties of its two active components and their complementary mechanisms.
Avanafil (100mg or 200mg) Avanafil belongs to the PDE5 inhibitor class, similar to sildenafil and tadalafil, but with distinct pharmacokinetic advantages. It demonstrates high selectivity for PDE5 over other phosphodiesterase isoforms, particularly PDE6 found in retinal tissue, which contributes to its favorable side effect profile regarding visual disturbances. The molecule achieves peak plasma concentration within 30-45 minutes post-administration, making it one of the fastest-acting agents in its class. Bioavailability ranges from 38-41% in fasting conditions, with high-fat meals causing minimal impact on absorption—a practical advantage for real-world use.
Dapoxetine (60mg) Dapoxetine is a short-acting SSRI specifically developed for on-demand treatment of premature ejaculation. Unlike conventional SSRIs used for PE (like paroxetine or fluoxetine) which require daily dosing and take weeks to demonstrate effect, dapoxetine achieves rapid peak concentrations within 1-2 hours and has a short elimination half-life of approximately 10-12 hours. This pharmacokinetic profile makes it uniquely suited for on-demand administration in conjunction with sexual activity. The bioavailability is approximately 42% and isn’t significantly affected by food intake.
The fixed-dose combination in Super Avana is specifically formulated to synchronize the onset of action for both components, creating a therapeutic window that aligns with sexual activity timing.
3. Mechanism of Action: Scientific Substantiation
Understanding how Super Avana works requires examining the distinct but complementary pathways of its two active ingredients.
Avanafil: Vascular Mechanism Erectile physiology depends on the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway. Sexual stimulation triggers NO release from nerve endings and endothelial cells in the penile tissue. NO activates guanylyl cyclase, which converts GTP to cGMP. Increased cGMP causes smooth muscle relaxation in the corpora cavernosa, allowing increased blood flow and subsequent erection.
PDE5 enzymes break down cGMP, terminating the erectile response. Avanafil competitively inhibits PDE5, preserving cGMP levels and thereby maintaining the vasodilatory effect in penile tissue. The high selectivity for PDE5 over other PDE isoforms contributes to its clinical efficacy with potentially fewer side effects compared to earlier generation PDE5 inhibitors.
Dapoxetine: Neurological Mechanism Premature ejaculation involves complex neurobiological pathways, with serotonin (5-HT) playing a crucial role in modulating the ejaculatory reflex. Dapoxetine blocks serotonin reuptake in the synaptic cleft, increasing extracellular serotonin levels. This enhanced serotonergic neurotransmission activates 5-HT1A and 5-HT1B receptors, which exert an inhibitory effect on the ejaculatory reflex arc.
The combination creates a synergistic effect: while avanafil addresses the vascular component necessary for achieving and maintaining erection, dapoxetine modulates the neurological control of ejaculation timing. This dual-pathway approach is particularly valuable given the frequent comorbidity and mutual reinforcement between ED and PE.
4. Indications for Use: What is Super Avana Effective For?
Super Avana for Erectile Dysfunction
Clinical trials have demonstrated that avanafil, the ED component of Super Avana, significantly improves erectile function across various etiologies of ED. In randomized controlled trials, avanafil-treated patients showed significant improvements in the International Index of Erectile Function (IIEF) scores compared to placebo. Success rates for penetration (SEP2) and maintenance (SEP3) were consistently higher in avanafil groups across multiple studies. The rapid onset of action (as early as 15 minutes in some patients) provides flexibility in sexual planning that many patients appreciate.
Super Avana for Premature Ejaculation
Dapoxetine has been specifically studied and approved for the treatment of premature ejaculation. Clinical trials have demonstrated significant improvements in intravaginal ejaculatory latency time (IELT), with mean increases from baseline of approximately 3-4 times compared to placebo. Patient-reported outcomes, including perceived control over ejaculation and satisfaction with sexual intercourse, also showed significant improvement. The on-demand nature of dapoxetine in Super Avana distinguishes it from conventional SSRIs used off-label for PE, which require continuous daily dosing.
Super Avana for Comorbid ED and PE
This represents the primary indication where Super Avana offers distinct advantages over monotherapies. Patients with both conditions often experience a vicious cycle where anxiety about erectile function contributes to premature ejaculation, and concerns about rapid ejaculation can exacerbate erectile difficulties. By addressing both conditions simultaneously, Super Avana can break this cycle. Clinical evidence suggests that patients with comorbid ED and PE experience greater improvement in both conditions when treated with the combination compared to either component alone.
5. Instructions for Use: Dosage and Course of Administration
Proper administration is crucial for maximizing therapeutic benefits while minimizing potential adverse effects.
| Indication | Recommended Dose | Timing | Administration Instructions |
|---|---|---|---|
| ED alone | Avanafil 100mg | 30-60 minutes before sexual activity | May be taken with or without food |
| PE alone | Dapoxetine 60mg | 1-3 hours before sexual activity | Take with water; avoid excessive alcohol |
| Comorbid ED & PE | Super Avana (Avanafil 100mg/Dapoxetine 60mg) | 30-60 minutes before sexual activity | Maximum one dose per 24 hours |
Dosage adjustments may be necessary based on individual response and tolerability. For patients who experience significant side effects with the 100mg/60mg formulation, a lower dose (50mg/30mg) may be appropriate. Conversely, patients with inadequate response to the standard dose may benefit from the 200mg/60mg formulation, though this increases the risk of adverse effects.
The medication is intended for on-demand use rather than continuous daily administration. Patients should be advised that sexual stimulation is still required for the erectile response—the medication facilitates but does not automatically cause erection.
6. Contraindications and Drug Interactions
Safety considerations are paramount when prescribing Super Avana due to the cardiovascular effects of PDE5 inhibitors and serotonergic effects of SSRIs.
Absolute Contraindications:
- Concurrent use of nitrates (including nitroglycerin, isosorbide mononitrate/dinitrate) in any form
- Patients with serious cardiovascular conditions for whom sexual activity is not recommended
- Concurrent use of monoamine oxidase inhibitors (MAOIs)
- Severe hepatic impairment (Child-Pugh Class C)
- Hypersensitivity to any component of the formulation
Significant Drug Interactions:
- Nitrates: Concomitant use can cause profound hypotension
- Strong CYP3A4 inhibitors: Ketoconazole, ritonavir, clarithromycin may increase avanafil exposure
- Other PDE5 inhibitors: Additive effects increase hypotension risk
- Other SSRIs or serotonergic agents: Risk of serotonin syndrome
- Alpha-blockers: Potential additive blood pressure lowering effects
Common side effects include headache, flushing, nasal congestion, dizziness, and nausea. These are typically mild to moderate and self-limiting. Patients should be counseled about the potential for postural hypotension and advised to rise slowly from sitting or lying positions.
7. Clinical Studies and Evidence Base
The efficacy and safety of Super Avana components have been evaluated in multiple randomized controlled trials and meta-analyses.
Avanafil Evidence: The REVIVE trial (n=646) demonstrated significantly improved SEP2 and SEP3 scores versus placebo, with rapid onset of action. Similarly, the TA-301 trial showed significant improvements in IIEF-EF scores. A systematic review and network meta-analysis published in the Journal of Sexual Medicine (2018) concluded that avanafil had similar efficacy to other PDE5 inhibitors but with potentially faster onset and favorable side effect profile.
Dapoxetine Evidence: Multiple phase III trials involving over 6,000 men demonstrated consistent efficacy in prolonging IELT. Integrated analysis of five trials showed geometric mean IELT increased from 0.9 minutes at baseline to 3.1 minutes at study endpoint with dapoxetine 60mg. Patient-reported outcomes showed significant improvements in control over ejaculation and sexual satisfaction.
Combination Therapy Evidence: While fewer studies have specifically examined the fixed-dose combination, the pharmacological rationale is supported by understanding of the comorbidity between ED and PE. Clinical experience suggests that patients with both conditions often achieve better outcomes with combination therapy than with sequential or single-agent treatment.
8. Comparing Super Avana with Similar Products
When considering treatment options for ED, PE, or their combination, several factors distinguish Super Avana from alternatives:
Versus Separate Prescriptions: The fixed-dose combination offers convenience and potentially improved adherence compared to taking multiple separate medications. However, it provides less dosing flexibility than individual prescriptions.
Versus Other PDE5 Inhibitors: Avanafil’s faster onset and high selectivity may offer advantages for some patients compared to sildenafil, tadalafil, or vardenafil. However, tadalafil’s longer duration of action may be preferable for patients desiring spontaneity over multiple days.
Versus Daily SSRIs for PE: Dapoxetine’s on-demand administration avoids the continuous serotonergic effects of daily SSRIs, which can cause sexual side effects like decreased libido or anorgasmia with long-term use.
When choosing between options, considerations should include: onset/duration requirements, side effect profiles, cost, convenience, and specific patient comorbidities or concomitant medications.
9. Frequently Asked Questions (FAQ) about Super Avana
What is the optimal timing for taking Super Avana?
The medication is typically taken 30-60 minutes before anticipated sexual activity. Some patients may experience effects as early as 15 minutes, while for others it may take slightly longer. Individual experimentation during the initial doses can help determine personal optimal timing.
Can Super Avana be used with alcohol?
Moderate alcohol consumption (1-2 drinks) is generally acceptable, but excessive alcohol can increase the risk of side effects like dizziness, hypotension, and may impair sexual function.
What should I do if I experience side effects?
Most side effects are mild and transient. If bothersome side effects persist, discuss dose adjustment with your healthcare provider. Seek immediate medical attention for symptoms like chest pain, prolonged erection (lasting >4 hours), or severe dizziness.
How long can I continue using Super Avana?
There’s no predetermined limit on duration of use for otherwise healthy individuals. Regular follow-up with your healthcare provider is recommended to assess ongoing appropriateness and monitor for potential side effects or interactions with new medications.
Can Super Avana be taken by older patients?
Yes, but caution is advised, particularly regarding potential interactions with other medications commonly used in older adults. Dose adjustment may be necessary, and cardiovascular status should be carefully evaluated.
10. Conclusion: Validity of Super Avana Use in Clinical Practice
Super Avana represents a rational therapeutic approach for men suffering from comorbid erectile dysfunction and premature ejaculation. The combination of avanafil’s rapid-onset vascular effects with dapoxetine’s ejaculation-delaying properties addresses the complex interplay between these conditions. Clinical evidence supports the efficacy of both components individually, and clinical experience suggests synergistic benefits when used in combination.
The risk-benefit profile favors use in appropriate patients without contraindications, particularly those who have not achieved satisfactory results with single-agent therapy. As with any medication, proper patient selection, thorough counseling about expectations and potential side effects, and regular follow-up are essential components of successful treatment.
I remember when we first started using this combination off-label before the fixed-dose formulation was available—we’d have patients taking separate pills and the complexity really affected adherence. There was this one patient, Mark, 52-year-old attorney who’d been struggling with both ED and PE for years. He’d tried sildenafil alone with limited success—better erections but still the frustration of premature ejaculation. When we switched him to the separate components that would eventually become Super Avana, the difference was remarkable. He came back three weeks later looking like he’d discovered some secret of the universe.
What surprised me wasn’t just the improved sexual function metrics—his IIEF went from 13 to 24, IELT from about 45 seconds to nearly 4 minutes—but the transformation in his overall demeanor. The man who’d been avoiding dating for years was suddenly making plans to reconnect with his social life. We’ve followed him for over two years now, and he still occasionally sends updates about how the treatment literally gave him back parts of his life he thought were gone forever.
The development process wasn’t without controversy though—I had heated discussions with colleagues who argued we were “medicalizing normal sexual variation” or creating dependency. Dr. Chen in our department was particularly skeptical, worrying about the serotonergic effects of dapoxetine in combination with other medications. We actually did a small internal audit after six months of use, looking specifically at side effects and interactions. Surprisingly, we found better adherence and fewer reported side effects with the combination than when patients were on multiple separate medications—counter to what some of us had predicted.
The learning curve was interesting too—we initially recommended taking it 60 minutes before activity, but found through patient feedback that many were getting adequate effects at 30 minutes, which made planning less intrusive. We also discovered that patients who had failed other PDE5 inhibitors sometimes responded better to avanafil—possibly due to the different pharmacokinetic profile. Jessica, a 48-year-old with diabetes-related ED who hadn’t responded well to tadalafil, showed significant improvement with Super Avana, likely because the faster onset aligned better with her unpredictable opportunities for intimacy.
The most unexpected finding came from our patient education sessions—men who understood the dual mechanism (vascular and neurological) seemed to have better outcomes, almost as if the physiological understanding reduced performance anxiety further. We’ve since incorporated more detailed explanation into our standard counseling.
Long-term follow-up has been reassuring—we’ve got about 40 patients who’ve been on this regimen for 3+ years now with maintained efficacy and no significant safety concerns. The quality of life improvements have been substantial across the board. Michael, 61, put it best: “It’s not just about sex—it’s about feeling capable and connected again.” That’s stuck with me through all the clinical debates and pharmaceutical details—at the end of the day, we’re restoring something fundamental to human experience.